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Genomic association analyses of complex traits demand statistical tools that are capable of detecting small effects of common and rare
variants and modeling complex interaction effects and yet are computationally feasible. In this work, we introduce a similarity-based
regression method for assessing the main genetic and interaction effects of a group of markers on quantitative traits. The method
uses genetic similarity to aggregate information from multiple polymorphic sites and integrates adaptive weights that depend on allele
frequencies to accomodate common and uncommon variants. Collapsing information at the similarity level instead of the genotype
level avoids canceling signals that have the opposite etiological effects and is applicable to any class of genetic variants without the
need for dichotomizing the allele types. To assess gene-trait associations, we regress trait similarities for pairs of unrelated individuals
on their genetic similarities and assess association by using a score test whose limiting distribution is derived in this work. The proposed
regression framework allows for covariates, has the capacity to model both main and interaction effects, can be applied to a mixture of
different polymorphism types, and is computationally efficient. These features make it an ideal tool for evaluating associations between
phenotype and marker sets defined by linkage disequilibrium (LD) blocks, genes, or pathways in whole-genome analysis.Introduction
Marker-set analysis refers to the joint evaluation of a group
of markers for genetic association. These markers might
be of various polymorphism types (e.g., a mixture of SNP,
insertion-deletion variants [INDEL], block substitutions,
copy-number variants, or inversion variants) but share
certain common genomic features, such as participating
in the same pathway, being in high linkage disequilibrium
(LD), or being located within the same gene or conserved
functional region. Marker-set analysis has drawn great
attention in recent genome-wide and sequence-based
association studies. It assesses the joint associationofpoten-
tially correlated and interacting loci. It amplifies the detect-
ability of the causal signalsby aggregating small effects from
multiple individual loci. Furthermore, because sequences
and functions of genes are highly consistent across popula-
tions and species, a marker-set analysis increases the inter-
pretability and replicability of the association findings. For
whole-genome scans, it also offers a naturalway of reducing
the total number of tests and hence improves power by
reducing the multiple-testing burden. For sequence-based
studies,marker-set analysis accumulates informationacross
multiple rare mutations and has a greatly enhanced power
to detect rare variants that are hard for researchers to
identify by traditional analysis methods.
A variety of methods are available for detecting marker-
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The Americcombined methods1,2 for single-marker tests to multi-
marker tests with a genotype- or haplotype-based scoring.
Many recent methods fall in between the two extremes.
These methods collapse information from all markers in
the set and achieve a better balance between information
and degrees of freedom. Depending on how the individual
marker information is combined, we can roughly classify
these approaches into four categories. Methods in the
first category use the weighted sum of genotypes across
markers, for example the LD-based weighting method,3
the weighted Fourier transform,4 and the PCA-based
methods.5,6 Recently, special versions of the weighted-
sum methods based on allele frequencies were proposed
to target rare variants.7–10 Methods of the second type
model the genetic similarity of pairs of individuals and
are also referred to as U-statistics approaches.11–19 Methods
of the third type are variance-component (VC) methods,
which treat individual genetic effects as random effects
and test for the corresponding VC to detect the global effect
of a gene. Methods of this type include the SNP random-
effects model,20,21 haplotype random-effects model,22 and
kernel-based methods.23–25 The fourth category includes
other approaches that do not fit into the above categories,
such as the c-alpha test,26 the group additive regression
model,27 Tukey’s model,28 and entropy-based methods.29
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on detecting genetic main effects, here we focus on
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interactions. Identifying genetic variants with heteroge-
neous effects under different environmental exposures
is crucial for understanding individualized medicine,
studying pharmacogenetics, characterizing underlying
biological mechanisms, and uncovering unexplained
heritability.30,31 Marker-set analysis provides an ideal
framework for the study of G 3 E interactions. The marker
set, either defined by genes, pathways, or functions,
provides a biologically sensible unit for the G component,
and the loci in a set can be assessed jointly for whether
their effects are modified under different environmental
exposures. In addition, the potential power gain brought
by the marker-set analysis—either through aggregating
genetic signals or by reducing multiple-testing penalty—
can alleviate the data-hungry nature of detecting G 3 E
interactions. Typically, a G 3 E test would require sample
sizes at least four times larger than a main effect test for
detecting an effect of comparable magnitude.30–33 Further-
more, many G3 E studies are based on conceptual models
for candidate pathways, in which a set of genes are selected
and studied together.31,34 Marker-set analysis offers a suit-
able tool for the evaluation of the overall effect of the postu-
lated pathways when assessing G 3 E interactions.
The marker-set G 3 E method we present focuses on
quantitative traits and uses pairwise genetic similarity as
a tool to aggregate marker information (i.e., the second
category in the above method categorization). Our
approach differs from those in the literature on gene/
pathway level analysis in the following aspects. First, we
introduce a framework for incorporating interaction effects
in similarity-based methods. To be useful for G 3 E studies
with either confirmatory or exploratory aims, we develop
a series of tests to suit different purposes, including a test
for detecting G 3 E interactions, a test for detecting
marginal main effects, and a joint test for detecting the
overall association induced either by genetic main effects
or by G 3 E interactions. The joint test serves as a good
tool when little is known a priori about the genetic hetero-
geneity across exposure strata and provides power across
a wide range of the unknown underlying true structures.
Second, the proposed method can collapse information
from amixture of different types of variants and is designed
to detect common and uncommon variants. Both are desir-
able features when more classes of DNA variants are avail-
able. Finally, we illustrate how similarity-based collapsing
methods can be equivalent to VC methods (i.e., category
3 in the method categorization), which are found to have
better main-effect performance than several other marker-
set approaches.24,35–37 Through simulation, we show the
validity of the test and investigate the power of the pro-
posed approach under a wide range of scenarios. We illus-
trate the utility of the proposed method by using the
samples from the Vitamin Intervention for Stroke Preven-
tion (VISP) trial. In this study, candidate genes across the
genome were selected for the evaluation of the gene and
gene-age interaction effects on the change in fasting homo-
cysteine (Hcy) level following a 2 hr methionine load test.278 The American Journal of Human Genetics 89, 277–288, August 1Material and Methods
Gene-Trait Similarity Regression for G
and G 3 E Effects
We use the following notations. For individual i ði ¼ 1; 2;.;nÞ; let
Yi be the continuous trait, Xi be the K31 covariate vector
excluding the intercept term and standardized to mean ¼ 0 and
variance ¼ 1, and Gm;i be the allele-count vector of marker m for
person i; with the length equal to the number of distinct alleles
at marker m (denoted by [m), m ¼ 1;2;/;M. For example,
Gm;i ¼ ½2;0 if person i has genotype 11 at SNP m and ¼ ½1;1 if
person i has genotype 10. To fix the idea, we consider K ¼ 1, but
the method described here also applies to K > 1:
For each pair of individuals i and j, we measure the trait simi-
larity Zij and genetic similarity Sij of the targeted marker set. We
then regress the trait similarity on the genetic similarity and
detect gene-trait association by testing for the significance of rele-
vant regression coefficients. The trait similarity Zij is quantified
through trait covariance by taking the product of the trait resid-
uals of subjects i and j. Let mi be the subject-specific mean of trait
value adjusted for the covariate information; then we set
Zij ¼ ðYi  miÞðYj  mjÞ; where mi ¼ g0 þXig and ðg0;gÞ is the
covariate effects including the intercept. The genetic similarity
Sij is measured by the average of the weighted allele matching
score (weighted matching score for short) between subjects i
and j across the M markers. It takes the form of Sij ¼
1=M3
PM
m¼1G
T
m;iWmGm;j, in which Wm is an [m3[m matrix
that specifies the weighting scheme. As an illustration,
consider a SNP and the weight Wm ¼ I232. Then SAA;AA ¼ 4,
SAA;Aa ¼ 2, and SAA;aa ¼ 0. When quantifying genetic similarity,
one can use weights based on allele frequencies, the degree of
evolutionary conservation, or the functionality of the variations
to better target genetic variants of certain features (e.g., rare, func-
tional).15,25,38 For example, to upweight similarities contributed
by rare variants, we define the frequency of allele a at marker m
as qa;m and set Wm ¼ diagf1=qa;mg or diagf1= ﬃﬃﬃﬃﬃﬃﬃﬃqa;mp g to upweight
the similarity in rare alleles.23,24
The proposed gene-trait similarity regression model has the
following form:
E

Zijj X;H
 ¼ b3 Sij þ d3 Sij3XiXj; isj: (Equation 1)
Because baseline and covariate effects have been adjusted for
Zij; the regression has a zero intercept and does not have the cova-
riate term XiXj. This contention will become more obvious from
the viewpoint of variance components in the following para-
graph. Equation 1 incorporates information about genetic main
effects and gene-environment interactions and hence allows the
possibility of a genetic effect to be modified by an environmental
exposure. Under Equation 1, one can evaluate the overall genetic
association by performing a joint test of genetic main effects and
gene-environment interactions for H0 : b ¼ d ¼ 0. To assess gene-
environment interactions only, one can perform a G 3 E test by
examining H0 : d ¼ 0. Finally, one can evaluate the marginal
main effects by examining the main effect term and testing for
H0 : b ¼ 0 under the constraint of d ¼ 0. We refer to this test as
the G test. The G test can be used as a subsequent test when a
G 3 E test fails to reject H0, or it can be used as an alternative
way to detect the overall genetic association. Because interactive
factors can often exhibit a marginal effect even when the interac-
tion terms are not modeled,39,40 the G test is often used to perform
genome screening in common practice. Compared to the joint2, 2011
test, the G test uses fewer degrees of freedom and hence is more
powerful when there are no gene-environment interactions or
when the interaction effects are big, but it might be less powerful
when the genetic effect is restricted to the exposure group.41
The test statistics for G 3 E, G, and joint tests can be derived
through the equivalence between the similarity regression models
and the haplotype random-effects model.17 Consider a working
haplotype random-effects model:
Yi ¼ g0 þXigþ HTi bþXiHTi lþ ei; (Equation 2)
where ei  Nð0; sÞ,Hi is the L31 haplotype vector, L is the number
of distinct haplotypes observed in the population, bL 3 1  N
ð0; tRÞ;lL31  Nð0;fRÞ; and R is an L3L matrix in which the
ðh; kÞ th entry is equal to the similarity between haplotypes h
and k, quantified by the weighted matching score. Under the
working mixed model (Equation 2), the trait covariance between
individuals i and j ðisjÞ is
cov

Yi;Yjj X;H
 ¼ HTi covðbÞHj þXiHTi covðlÞHjXj
¼ t3HTi RHj þ f3XiXj3HTi RHj
¼ t3 Sij þ f3XiXj3 Sij
(Equation 3)
The last line follows from the fact that HTi RHj ¼ 1=M3PM
m¼1G
T
m;iWmGm;j
17. Comparing Equations 1 and 3, we have
b ¼ t and d ¼ f: That is, the regression coefficients in the simi-
larity regression are the variance components in the mixed model
(Equation 2). Therefore, following similar derivations in Tzeng
and Zhang22 and Zhang and Lin,42 we obtain the score test statis-
tics for G 3 E test, G test, and the joint test as follows:
TG3E ¼ YTP1DSDP1Yj f¼0;t¼bt ;s¼bs ;
TG ¼ YTP0SP0Yj f¼0;t¼0;s¼ ~s ;
and
Tjoint ¼ YTP0ðSþDSDÞP0Yj f¼0;t¼0;s¼ ~s :
In the above equations, YTn31 ¼ ðY1;/;YnÞ, Dn3n ¼ diagfXig;
and S ¼ fSijg where Sij ¼ HTi RHj; matrix Pt ¼ V1t 
V1t XðXTV1t XÞ1XTV1t ;t ¼ 0;1; where V0 ¼ sI;V1 ¼ tSþ sI:
The quantities ðbt; bsÞ are the REML estimates for ðt; sÞ obtained
under H0 : f ¼ 0, and ~s is the REML estimate for s under
H0 : f ¼ t ¼ 0. These estimates are given in Appendix A. As shown
in Appendix B, these test statistics follow a weighted c2 distribu-
tion, and the p values can be calculated with the three-moment
approximation.43,44
There are a few remarks regarding the similarity-based marker-
set methods. The similarity regression aggregates marker informa-
tion through a sum of genotype similarity across markers instead
of a sum of genotypes. Compared to genotype sums, aggregating
information through similarity can prevent signals of opposite
directions from being canceled. In addition, because Gm;i takes
integer or dosage counts and can be of any length, this approach
can work with typed and imputed genotype calls and is applicable
to a mixture of different types of variants without having to
dichotomize the variants.Simulation Studies
We performed simulations based on HapMap 3 data to assess the
performance of the proposed tests. We obtained a haplotype
population consisting of 234 phased haplotypes from chromo-
some 21 of the CEU (Utah residents with ancestry from northernThe Americand western Europe) samples in HapMap 3. To obtain a variety of
risk allele frequencies and LD patterns of a marker set, we defined
amarker set as a 10 SNP region, and used a nonoverlapping sliding
window on chromosome 21 to obtain 1734 regions. Given
a marker-set region, we generated haplotypes for 500 individuals
by randomly sampling 500 pairs of haplotypes with replacement
from the 234 haplotypes under a Hardy-Weinberg equilibrium
assumption. Because the rarest allele frequency we can obtain
is 1=234z0:004, we used a relatively small sample size (n ¼ 500)
to assure genetic heterogeneity attributable to rare mutations.
Given a 10 SNP region, the 5th and the 10th SNPs were set to be
the risk loci, and their genotypes for individual i are denoted by G1i
and G2i˛f0;1;2g; respectively. We generatedXi  Nð0;1Þ: Then on
the basis of the genetic and covariate information of individual i,
the trait value Yi was sampled from a normal distribution with
mean ¼ g0 þ g1Xi þ gG1G1i þ gG2G2i þ gGE1XiG1i þ gGE2XiG2i and
variance ¼ v2; where g0 and g1 were set to be 1, and v2 was deter-
mined so that the heritability was around 0.1 to 0.2. For type I
error rate analysis, we set ðgG1 ;gG2 ;gGE1 ;gGE2 Þ ¼ ð0;0;0;0Þ for all
three tests and also ð0:2;0:2;0;0Þ forG3 E test. For power analysis,
we set ðgG1 ;gG2 ;gGE1 ;gGE2 Þ ¼ ð0:25;0:25;0:3;0:3Þ: These values
were chosen so that the power of the joint tests is not too close
to 1, whereas the power of G3E and G tests is not too close to
the nominal level of 0.0005.
Each region was analyzed with the proposed similarity regres-
sion with three weighting schemes considered in the litera-
ture:23,24 (1)Wm ¼ diagf1=qmg(referred to as SIM1), (2) Wm ¼
diagf1= ﬃﬃﬃﬃﬃﬃqmp g(referred to as SIM2), and (3) Wm ¼ diagf1g(referred
to as SIM0). The results were compared to two benchmark
methods, the single-SNP minimum-p-value method (referred to
as SNP) and the multi-SNP haplotype-based method (referred to
as HAP). In all analyses, the two risk loci were excluded, and the
phase information was removed. For the minimum p value
method, we used the minimum of the p values from the G 3 E,
G and joint tests for the eight SNPs, and the significance threshold
was determined with the multiple-testing correction method of
Moskvina and Schmidt.45 This method estimates the effective
number of independent tests for correlated SNPs at a given overall
type I error rate and calculates the significance level for the indi-
vidual tests accordingly. For the haplotype-based analysis, we
used the widely used R package haplo.stats to carry out standard
haplotype regression analysis. Specifically, we used haplo.glm46
for the G 3 E test and haplo.score47 for the G test. We did not
perform the joint test at the haplotype level because it is not
supported by this program. Haplotypes with frequencies less
than the program default threshold (i.e., 0.01) were pooled into
the baseline haplotype.Results
Simulation Studies
To evaluate type I error rates, we randomly selected six of
1734 regions on chromosome 21 to represent six different
scenarios: two levels of disease allele frequencies (q ¼ 0.1
and 0.3) combined with three levels of LD pattern (high,
medium, and low). The LD pattern was summarized
with the average of the 16 R2 values, where each value
is the LD between an observed marker (eight in total)
and a risk locus (two in total). A larger LD value reflects
stronger correlation between the observed markers andan Journal of Human Genetics 89, 277–288, August 12, 2011 279
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Figure 1. Type I Error Rates of the
Proposed Methods
The type I error rates are shown on the
scale of 102, 103, and 104 for nominal
level a ¼ 0:05, 0.005, and 0.0005, respec-
tively. The regions are randomly selected
from chromosome 21 to represent six
different scenarios listed on the x axis:
two levels of disease allele frequencies
(q ¼ 0:1 and 0.3) combined with three
levels of LD pattern (high, medium, and
low). A high-LD value reflects stronger
correlation between the observed markers
and the two unobserved risk loci. The
panel titles indicate the value of
ðgG1;gG2;gGE1;gGE2Þ, that is the effect
sizes of the main genetic effects and gene-
environment interactions at the two risk
loci used in generating simulated data.
Each of the type I error rates is calculated
on the basis of 50,000 replications
for ðgG1 ;gG2 ;gGE1 ;gGE2 Þ ¼ ð0;0;0;0Þ and
20,000 replications for ð0:2;0:2;0;0Þ. The
type I error rates for HAP-G at a ¼ 0:0005
are given below as some are beyond the
plotting range: (0.00454, 0.00266, 0.0023,
0.00158, 0.00794, and 0.00072).the unobserved risk loci, hence the value reflects the
informativeness of the observed markers for the risk
loci. Each of the type I error rates was calculated on the
basis of 50,000 replications for ðgG1 ;gG2 ;gGE1 ;gGE2Þ ¼
ð0;0; 0;0Þ for all tests and 20,000 replications for
ð0:2;0:2;0;0Þ for G 3 E test. The results (Figure 1) indicate
that the type I error rates were around the nominal
levels considered (i.e., a ¼ 0:05, 0:005, and 0:0005) for
all methods in most scenarios. The exceptions tend to
occur in the haplotype G 3 E tests, where the type I errors
can be inflated because of the presence of rare haplotypes.
Inflation at larger a levels can often be eliminated by
using a slightly higher threshold (e.g., 0.02, as opposed
to the default value of 0.01) that pools uncommon haplo-
types into the baseline group. To avoid any potential
impact that modifying the default threshold might
induce, we still used the threshold value of 0.01 in our
power analysis.
The power was evaluated for each of the 1734 regions on
the basis of 100 replications at the nominal level of 0.0005.
The results are shown in Figure 2 (G 3 E test), Figure 3 (G
test), and Figure 4 (joint test). The 1734 regions were
grouped into 12 categories, combinations of the four
scenarios of allele frequencies and the three LD patterns.
The risk allele frequencies from rare to common are catego-
rized as follows: (A) both allele frequencies are less than
0.05, (B) sums of allele frequencies that are less than 0.3
but excluding those in (A), (C) sums of allele frequencies
that are between 0.3 and 0.6, and (D) sums of allele
frequencies that are greater than 0.6. The clustering of
LD patterns is based on the following thresholds: an
average R2 > 0:6 for high, an average R2˛ð0:25;0:6Þ for
medium, and an average R2 < 0:25 for low.280 The American Journal of Human Genetics 89, 277–288, August 1A similar pattern was observed across Figures 2–4, hence
we concentrate on explaining Figure 2. In regions that
exhibit low LD (LD-L), all three methods lacked power and
had roughly equal performance. The exception is in (A),
where the SIM1 method performed worse than the other
two. The situation that all three methods had similarly
low power is not surprising because LD-L represents regions
that contained markers with little information about the
two risk loci. The lone exception in LD-L (A) can be ex-
plained by the fact that the SIM1 method is best applied
in scenarios where a large number of markers have at least
medium-level LD with the risk loci, but in LD-L (A), such a
scenario only occurred in 13% of the regions. On the other
hand, in 60% of the regions, the majority of the markers
had no LD with the risk loci, but either one single marker
was in perfect LD with one of the risk loci, or two markers
were in very high LD with each of the risk loci. The former
cases tend to favor the SNP methods, whereas the latter
tend to favor the HAP methods (and the remaining 27%
were regions where all markers had extremely low LD with
the risk loci). In the scenarios of LD-L with (B), (C), and
(D), we did not observe such a large proportion of extreme
cases, and this resulted in a more comparable performance
of the three methods. Finally, compared to regions with
LD-L, in the regions with medium LD (LD-M), we observed
a uniform increase of power in all three methods, and SIM1
has a slightly greater power. The power gain was more
pronounced for high-LD regions (LD-H), where SIM1
showed more power than the other two methods.
To understand the impact of different weighting
schemes in the similarity regression, we repeated the
same analysis with SIM1, SIM2, and SIM0 (Figure 5).
Because the overall patterns were similar across different2, 2011
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Figure 2. Boxplot of Power of G 3 E Test from the 1734 Regions on Chromosome 21
The3 sign indicates the average power. The power at a region is calculated on the basis of 100 replications at a nominal level of 0.0005.
The results are grouped into 12 categories on the basis of frequencies of the risk alleles and LD patterns. The risk allele frequencies from
rare to common are categorized as (A) both allele frequencies < 0:05; (B) sums of allele frequencies < 0:3 but excluding (A); (C) sums of
allele frequencies between 0.3 and 0.6; and (D) sums of allele frequencies > 0:6. The clustering of LD patterns is done according to the
following thresholds: average R2 > 0:6 for high (LD-H), average R2˛ð0:25;0:6Þ for medium (LD-M), and average R2 < 0:25 for low (LD-L).tests, we present the results from the G 3 E and G tests.
Figure 5 presents the box plots of power for the same
regions as shown previously, except that panels (C) and
(D) in Figures 2–4 were grouped together to represent
common-variant scenarios. We also marked the corre-
sponding average power of SNP (solid line) and HAP
(dotted line) for comparison. We observed the following
features: (1) SIM0 and SIM2 had very similar power in
almost all situations; (2) when risk alleles are common
(i.e., [C] and [F]), SIM2 and SIM0 had similar or slightly
better power than SIM1, although the difference was not
very obvious; and (3) when the risk alleles are uncommon
or rare, SIM1 started to gain some traction in improving
power. The power improvement became more substantial
for rarer alleles. For example, in situations with a moderate
LD level, SIM1 had higher power than SNP and HAP,
whereas SIM2 and SIM0 did not.
Application to Real Data
We applied the similarity regression on samples collected
from the VISP trial. VISP was a multicenter, double-blind,
randomized, controlled clinical trial that aimed to study
the effect of vitamins on preventing recurrent stroke. The
VISP trial was conducted under institutional review board
approval at the Wake Forest University School of Medicine
and at each of the clinic sites and adhered to the tenets ofThe Americthe Declaration of Helsinki. Written informed consent was
obtained from all patients participating in the study. The
trial enrolled patients who were 35 or older with a nondis-
abling cerebral infarction [MIM 601367] within 120 days
of randomization and Hcy levels in the top quartile for
the U.S. population. Subjects were randomly assigned to
receive daily doses of either a high-dose formulation (con-
taining 25 mg vitamin B6, 0.4 mg vitamin B12, and 2.5 mg
folic acid) or a low-dose formulation (containing 200 mg
vitamin B6, 6 mg vitamin B12, and 20 mg folic acid). The
patients were followed up for a maximum of 2 years, and
the average follow-up time was 1.7 years. About 2100 of
the VISP participants provided DNA samples, and geno-
type information was collected from candidate genes
selected across the genome that are involved in homocys-
teine metabolism, stroke risk, and atherosclerosis [MIM
209010]. After quality control, the dataset consists of
1944 subjects and genotypes of 1393 SNPs collected from
215 candidate genes. More details on the VISP trial and
VISP genetic study can be found in Toole et al.48 and Hsu
et al.,49 respectively.
Our analysis here focused on the genetic influence on
the Hcy level obtained from a 2 hr methionine load test
measured at baseline. It has been suggested that Hcy level
can be used to predict risk of recurrent stroke and symp-
tomatic coronary heart disease, and genetic variationsan Journal of Human Genetics 89, 277–288, August 12, 2011 281
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Figure 3. Boxplot of Power of G Test from the 1734 Regions on Chromosome 21
The 3 sign indicates the average power. The power at a region is calculated on the basis of 100 replications at a nominal level 0.0005.
The results are grouped into 12 categories on the basis of frequencies of the risk alleles and LD patterns. The risk allele frequencies from
rare to common are categorized as (A) both allele frequencies < 0:05; (B) sums of allele frequencies < 0:3 but excluding (A); (C) sums of
allele frequencies between 0.3 and 0.6; and (D) sums of allele frequencies > 0:6. The clustering of LD patterns is done according to the
following thresholds: average R2 > 0:6 for high (LD-H), average R2˛ð0:25;0:6Þ for medium (LD-M), and average R2 < 0:25 for low (LD-L).might be attributed to mild to moderate hyperhomocysti-
nemia [MIM 603174]. Given that the Hcy level tends to
increase with age, we also investigated the potential
gene-age interaction effects on Hcy. We conducted gene-
based analyses; we used the proposed SIM1 method to
assess the significant level of each gene and compared it
to the available benchmark, SNP, and/or HAP methods.
As in the original study,49 we adjusted for age, sex, and
race in each analysis. The Bonferroni threshold for p value
is 0:05=215 ¼ 2:333104:
Wefirst used the joint test toperformagene-based scan to
evaluate the gene and gene-age effects on the change in
postmethionine load Hcy level (i.e., postmethionine load
test Hcy  baseline fasting Hcy). If a gene is rejected by
a joint test, the G 3 E and G tests can be used to further
refine the sources of identified signals. The joint test is a
suitable screening tool for scenarios in which the under-
lying gene-age interaction mechanism is little known32,41
because it assesses the genetic main effect and gene-age
interactions simultaneously. The p values of the testing
results for each gene (sorted by gene names) are shown in
Figure 6. For joint tests, one gene was found to be
significant (CBS [MIM 613381]), and both SIM1 and SNP
tests yield significant p values. The p value of the SIM1 joint
is 2:463105, and the follow-up analysis reveals that the
signal is caused by the genetic main effect instead of gene-282 The American Journal of Human Genetics 89, 277–288, August 1age interactions: the p value of SIM G 3 E is 0:614, and
the p value of SIM G is 1:993106. The SNP joint test has
the adjusted minimum p value (adjusted for the 10 typed
SNPs inCBS) of 2:063105. The adjustedminimump value
is obtained by 1 ð1 raw p valueÞke f f where ke f f ¼ 7:59
is the effective number of independent tests estimatedwith
the method of Moskvina and Schmidt45 after accounting
for the LD in CBS. The adjusted minimum p value for the
SNP G 3 E test is 0.700, and for SNP G test it is
9:423106. Finally, the HAP G 3 E test yielded a p value
of 0:362, and HAP G test yielded a significant p value of
1:023105. Variants inCBShavepreviously beenassociated
with postmethionine load Hcy levels and change in Hcy
levels.49–52 A common 68 bp insertion at the intron
7-exon 8 boundary of CBS and the 31 bp variable number
of tandem repeats (VNTR) might be genetic determinants
of postmethionine load Hcy levels. Because postmethio-
nine load Hcy levels are found to have an increased risk
for cardiovascular disease, CBS could be also considered
a risk factor for cardiovascular disease.Discussion
Association analyses at the gene, pathway, and exon
levels (here by marker-set analysis) hold great promise in2, 2011
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Figure 4. Boxplot of Power of Joint Test from the 1734 Regions on Chromosome 21
The3 sign indicates the average power. The power at a region is calculated on the basis of 100 replications at a nominal level 0.0005. The
results are grouped into 12 categories on the basis of frequencies of the risk alleles and LD patterns. The risk allele frequencies from rare to
common are categorized as (A) both allele frequencies < 0:05; (B) sums of allele frequencies < 0:3 but excluding (A); (C) sums of allele
frequencies between 0.3 and 0.6; and (D) sums of allele frequencies > 0:6. The clustering of LD patterns is done according to the
following thresholds: average R2 > 0:6 for high (LD-H), average R2˛ð0:25;0:6Þ for medium (LD-M), and average R2 < 0:25 for low
(LD-L).evaluating modest etiological effects of genes with data
from genome-wide association studies (GWAS) or next-
generation sequencing. However, currently available
methods tend to target either rare or common variants
but not both, assume same-direction effects for loci within
a marker set, use a testing framework that cannot accom-
modate covariates, or do not have the capacity to assess
interaction effects. In this article, we propose a flexible,
powerful and computationally efficient method to con-
duct marker-set analysis for assessing gene and gene-
environment interactions on quantitative traits. The pro-
posed method is constructed via a similarity regression
framework under which we regress trait similarity on
genetic similarity. The framework incorporates interaction
effects, can adjust for covariates, and is applicable to both
observed and imputed dosage genotypes. We develop a
series of statistical tests that can be used for genetic
marginal main effects, G 3 E interactions, or the joint
effect of the two. We demonstrated that a similarity regres-
sion is equivalent to a haplotype random-effects model.
The equivalence enabled us to analytically derive the
asymptotic distributions of the test statistics and provide
a permutation-free procedure to assess significance. TheThe Americsoftware implementing the proposed methods is available
at the authors’ website (see Web Resources).
The proposed method uses genetic similarity to aggre-
gate information across markers and integrates adaptive
weights dependent on allele frequencies to accommodate
common and uncommon variants. Collapsing informa-
tion at the similarity level instead of the genotype level
avoids canceling signals with opposite etiological effects
and is applicable to any class of genetic variants without
having to dichotomize the allele types. As demonstrated
in the simulation, incorporating frequency weights gives
the method satisfactory power for detecting both common
and uncommon variants. The simulation results also
reveal that its performance is sensitive to the signal-
to-noise ratio (e.g., LD) among all loci included in the
marker-set analysis. The higher the ratio is, the greater
the power gain for the proposed methods. As discussed
in the next paragraph, it is possible to increase the
signal-to-noise ratio to maximize the chance of power
gain, such as by using functional, biological or LD informa-
tion to downweight the contribution from noise markers.
In practice, the underlying LD levels are not known and
will vary from regions to regions, it is less likely to choosean Journal of Human Genetics 89, 277–288, August 12, 2011 283
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Figure 5. Boxplot of Power of G 3 E Test and G Test with Different Weights—SIM1, SIM2, and SIM0—from the 1734 Regions on
Chromosome 21
The 3 sign indicates the average power of the method shown on the x axis. The solid and dotted lines indicate the average power of
SNP test and HAP test, respectively. The power at a region is calculated on the basis of 100 replications at a nominal level 0.0005.
The results are grouped into nine categories on the basis of frequencies of the risk alleles and LD patterns. The risk allele frequencies
from rare to common are categorized: (A and D) both allele frequencies < 0:05; (B and E) sums of allele frequencies < 0:3 but excluding
(A) and (D); (C and F) sums of allele frequencies > 0:3. The clustering of LD patterns is done according to the following thresholds:
average R2 > 0:6 for high (LD-H), average R2˛ð0:25;0:6Þ for medium (LD-M), and average R2 < 0:25 for low (LD-L).one best performing method in advance. In addition, in
GWAS, the low-LD scenario would occur less frequently
by design, and in sequencing studies the number of risk
loci in a set should be higher than what we considered in
the simulation. Given these considerations, the proposed
method can serve as a sensible and robust tool for
evaluating association of complex traits in whole-genome
marker-set analyses.
The inclusion of nonfunctional loci (i.e., nonrisk
markers that are not in LD with the risk loci) is a major
factor influencing the performance of all marker-set
approaches. Intelligently incorporating LD information
and biological knowledge into the collapsing process,
and downweighting the contribution of nonfunctional
markers will be a useful solution. In our framework, bio-
logical and functional information, as pioneered and
comprehensively reviewed in Price et al.10 and Schaid38
can be naturally incorporated through the weight matrix,
Wm: One unique feature of our weighting framework is
that it allows functional weights at the allele-specific
level (as opposed to locus-specific level), such as the284 The American Journal of Human Genetics 89, 277–288, August 1impact of a specific mutation sequence on protein func-
tions, structures, or stability. We are exploring mecha-
nisms to include genomic knowledge on the basis of
functionality, biological pathways, and system biological
networks.
One key requirement for the proposed method to have
power for both common and uncommon variants is that
the similarity level be weighted by allele frequency at
order k (i.e., qk). Although the principle is to upweight
similarities that are contributed by rare variants, there
are no clear rules for what the specific form of the weights
should be as a function of the allele frequencies. Kwee
et al.23 considered both k ¼ 1 and k ¼ 1=2 when calcu-
lating the IBS kernel and concluded that the former might
be too strong and the latter is more suitable in their
setting. Wu et al.24 therefore used k ¼ 1=2 in their work.
When aggregating information of multiple loci through
weighted genotype sum, Madsen and Browning8 consid-
ered their weights in the order of k ¼ 1=2 from the bino-
mial standard deviation (SD) viewpoint. Here, we evalu-
ated these different choices of k under our framework2, 2011
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Figure 6. p Values with Negative Log 10 Transformation for the VISP Trial Analysis
The x axis shows the gene IDs sorted by the alphabetic order of the gene names, and gene ID 39 is CBS. The red line indicates results
for SIM1, þ for SNP method, and 3 for HAP method. The results for the SNP methods are based on the adjusted minimum p values
that adjust for the multiple SNPs in a gene. The adjusted minimum p value is obtained by 1 ð1 raw p valueÞkeff , where keff is the
effective number of independent tests estimated with the method of Moskvina and Schmidt45 after accounting the LD among SNPs
in a gene. A few genes are not plotted on the graph for the HAP methods because of convergence failure at these locations. This failure
is mostly attributed to excessive number of SNPs in the gene.(i.e., SIM1 ½k ¼ 1; SIM2 ½k ¼ 1=2, and SIM0 ½k ¼ 0:). We
found that SIM2 might be too mild and tends to yield
similar results as the unweighted SIM0. One main differ-
ence between our weighting framework and others is
that we assign weights for every allele, whereas others
only assign weights for minor alleles. To illustrate the
impact of the difference, consider the similarity score
between a heterozygous pair. Our weights yield a score
of q
1=2
minor þ q1=2major, whereas those weights placed only on
minor alleles yield a bigger score of q
1=2
minor32 and give
a stronger weighting effect.
Simulation results also suggest that larger values of k can
greatly boost power for detecting rare variants, but it also
risks losing power when the risk variant is common. We
focused on SIM1 on the basis of its superior power for
rare variants and comparable power for common variants.
It is possible that the optimal weights would lie some-
where between k ¼ 1 and k ¼ 1=2, and we are investigating
further how to identify an optimal order. Alternatively,
one can use centered genotype scoring to account for
sharing of rarer alleles.53 To center the allele count vector
Gm;i, we define G

m;i ¼ Gm;i  Gm, where Gm is the vectorThe Americof population allele frequency for marker m. Then the
similarity score Sij is obtained by 1=M3
PM
m¼1G
T
m;iG

m;j.
The centering strategy bypasses the need of allele-
frequency-dependent weights and hence avoids the choice
of an order k. Studies to understand the pros and cons of
centering versus weighting strategies are underway.Appendix A: Expectation-Maximization Algorithm
for the REML Estimates of t and s When Testing
for G 3 E H0: f ¼ 0
Let u ¼ KTY be a set of n d linearly independent
contrasts of Y with KKT ¼ I  XðXTXÞ1XT and KTK ¼
In3n. Then the conditional distribution of u given b; de-
noted by f ðuj bÞ, is normal with mean KTHb and variance
sI and does not depend on the fixed effect g: Therefore,
the REML estimations of t and s can be based on its
marginal distribution f ðuÞ ¼ R f ðuj bÞf ðbÞdb: This moti-
vated an expectation-maximization algorithm based on
observed data u and missing data b. The complete-data
log likelihood is given byan Journal of Human Genetics 89, 277–288, August 12, 2011 285
log f ðu; b; t; sÞ ¼ log f ðuj b; t; sÞ þ log f ðb; t; sÞ
¼ n d
2
log s 1
2s

u KTHbTu KTHb
L
2
logt  1
2
logjRj  1
2t
bTR1b:
In the expectation step (E-step), we compute Qðt; s;
bt ðtÞ; bsðtÞÞ, the conditional expected value of log f ðu; b; t; sÞ
given the observed data u assuming ðt; sÞ ¼ ðbtðtÞ; bsðtÞÞ,
where btðtÞ and bsðtÞ are the estimates at the tth iteration.
Q

t; s; bt ðtÞ; bsðtÞhEhlog f ðu; b; t; sÞj u; bt ðtÞ; bsðtÞi
¼  n d
2
log s 1
2s
E
h
u KTHbTu KTHbu; bt ðtÞ; bsðtÞi
L
2
logt  1
2
log jRj  1
2t
E
h
bTR1bj u; bt ðtÞ; bsðtÞi:
In the maximization step (M-step), we solve for vQ=vt ¼
0 and vQ=vs ¼ 0 and obtain
bt ðtþ1Þ ¼ 1
L
E
h
bTR1bj u; bt ðtÞ; bsðtÞi ¼ 1
L
~bR1~b
1 þ tr

R1fW;
and
bsðtþ1Þ ¼ 1
n d E
h
u KTHbTu KTHbu; bt ðtÞ; bsðtÞi
¼

Y H~b
T
A

Y H~b

þ tr

HTAHfW:
In the above equations, A ¼ KKT ¼ I  XðXTXÞ1XT ,
~bhEðbj u; ; bt ðtÞ; bsðtÞÞ ¼ tRHTP1Y; and fWhvarðbju; bt ðtÞ;
bsðtÞÞ ¼ tR t2RHTPHR. The conditional moments of b
given u are obtained directly from the normality of the
joint distribution of ðu; bÞ: The calculation of the project
matrix P1 requires inverting the n3n nonsparse matrix
V1; which can be computational burdensome. To speed
up the computation, we rewrite
V1 ¼ tSþ sI ¼ s
n
I þ t
s
S
o
¼ s
n
I þ t
s
ELET
o
;
where S ¼ ELET , the eigenvalue decomposition ofmatrix S.
Then by the fact that ðI þ B1B2Þ1 ¼ I  B1ðI þ B2B1Þ1B2,
we can rewrite V11 ¼ 1=sfI  t=sEL½I þ ETt=sEL1ETg ¼
1=sfI  tEL½sI þ tETEL1ETg; in which the calculation
involves only an inversion of an L3Lmatrix.Appendix B: Derivation of the Score Test Statistics
and Their Asymptotic Distribution
For quantitative traits that follow a normal distribution
directly or after appropriate transformations, model (Equa-
tion 2) reduces to the following linear mixedmodel (LMM)
in matrix notation286 The American Journal of Human Genetics 89, 277–288, August 1Y ¼ 1g0 þ XgþHbþDHlþ ε; with b  Nð0; tRÞ;
l  Nð0;fRÞ; and ε  Nð0; sIÞ(Equation 4)
where YT ¼ ½Y1;/;Yn; 1 is an n31 vector of 1s, XT ¼
½X1;/;Xn;D ¼ diagfXig, and εTn31 ¼ ½e1;/; en: Because
our primary interest is to test the variance components f
and t, we consider the restricted maximum likelihood
(REML) log-likelihood function of variance compo-
nents ðt;f; sÞ :[REMLðt;f;YÞ ¼ flogjV j þ logjXTV1Xjþ
YTPYg=2; where V is the marginal variance of Y and
V ¼ fSþ tSþ sI, where S ¼ HRHT and S ¼ DSD; P ¼
V1  V1XðXTV1XÞ1XTV1 is the projection matrix
for the LMM (4).
Let Ufðf; t; sÞ and Utðf; t; sÞ denote the score functions
based on the REML function for f and t; respectively.
Simple algebra54 shows that under H0 : f ¼ 0;
Uf

0; bt ; bs ¼ v[REMLðt;f; sÞ
vf

f¼0;t¼bt ;s¼bs
¼ 1
2

YTP1SP1Y  trðP1SÞ
	
; (Equation 5)
and under H0 : t ¼ 0 (and with the constrain of f ¼ 0),
Ut

0;0; bs ¼ v[REMLðt;f; sÞ
vt

f¼0;t¼0;s¼~s
¼ 1
2

YTP0SP0Y  trðP0SÞ
	
: (Equation 6)
In the above equations, ð~t; ~sÞ are the REML estimates
of ðt; sÞ under H0 : f ¼ 0 as given in Appendix A, and ~s
the REML estimate of s when t ¼ f ¼ 0. Recall that
Pt ¼ V1t  V1t XðXTV1t XÞ1XTV1t where t˛f0;1g; and
V1 ¼ tSþ sI and V0 ¼ sI.
Null Distribution of the Score Statistics
for G 3 E Test and G Test
As shown in Tzeng and Zhang,22 the score statistics under
H0 arenot asymptotically normal because thedesignmatrix
H for the random effects b is not block diagonal and the
dimension of b is fixed. We thus use the first terms of the
score statistics as the testing statistics and obtain TG3E ¼
YTP1SP1Y=2 and TG ¼ YTP0SP0Y=2: Below we derive
the asymptotic null distribution of TG3E; and similar
steps can be used to obtain the distribution for TG: If
m ¼ 1g0  Xg; and Z ¼ V1=21 ðY mÞ, then Z follows a stan-
dard multivariate normal distribution. We rewrite
TG3E ¼ ZTð1=2V1=21 P1SP1V1=21 ÞZhZTCG3EZ, which is true
becausemTP1 ¼ 0by the fact ofP1 being aprojectionmatrix.
Define ei and hi, the eigenvector and eigenvalue of matrix
CG3E, respectively. Then TG3E ¼
Pc
i¼1hiðeTi ZÞ2h
PL
i¼1hi~Z
2
i ;
with ~Z
2
i follows a 1 degree-of-freedom chi-square distribu-
tion. In reality, ðt; sÞ is evaluated at their restricted
maximum likelihood estimates ðbt ; bsÞ. Following Tzeng
and Zhang,22 the distribution of TG3E can be approximated
by the distribution of
Pc
i¼1bhic2i1, where bhi’s are the nonzero2, 2011
eigenvalues of matrix CG3Ej
t¼bt ;s¼bs . The distribution of
TG3E can be approximated by the three-moment approxi-
mation method of.43 The level- a significance threshold is
estimated by k1 þ ðca  h0Þ3
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
k2=h0
p
, where kj ¼
P
i h
j
i ;h
0 ¼
k32=k
2
3 and ca is the a th quantile of c
2
h0 (i.e., chi-square
distribution with h0 degrees of freedom). Alternatively,
one can report the p value of the observed statistic TG3E
by P < c2h0 > c
, where c ¼ ðTG3E  k1Þ3
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
h0=k2
p þ h0.
By the same manner, the distribution of TG can also be
approximated by the three-moment approximation as
above, except that the eigenvalues his are obtained from
matrix CG ¼ 1=2V1=20 P0SP0V1=20 js¼~s.Null Distribution of the Score Statistics for Joint Test
The test statistic for the joint hypothesis H0 : f ¼ t ¼ 0 is
Tjoint ¼ TG þ T ð0ÞG3E, where TG is defined as before and
T
ð0Þ
G3E ¼ 1=2YTP0
P
P0Y, i.e., TG3E evaluated at f ¼ t ¼ 0
and s ¼ ~s: A direct (unweighted) sum is used here because
X has been prestandardized to mean ¼ 0 and variance ¼ 1,
and hence TG and TG3E are on the same scale. We found
that the performance of the unweighted sum is very
similar to that of the weighted sum, Twtjoint ¼ wG3TGþ
wG3E3T
ð0Þ
G3E, where the weights wi ¼ EðTiÞ=varðTiÞ. By
a similar derivation as in the G 3 E test, it can be shown
that the null distribution of Tjoint also has a weighted
chi-square distribution and can be approximated by the
three-moment approximation. The procedure is the
same as what mentioned for the G 3 E test, except
that the eigenvalues should be obtained from the matrix
Cjoint ¼ 1=2V1=20 P0ðSþ SÞP0V1=20 js¼~s.Acknowledgments
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